Background: Asenapine demonstrated superiority over placebo for mania in bipolar I disorder patients experiencing acute current manic or mixed episodes in 2 randomized, placebo-and olanzapine-controlled trials. We report the results of exploratory pooled post hoc analyses from these trials evaluating asenapine's effects on depressive symptoms in patients from these trials with significant baseline depressive symptoms. Methods: In the original trials (A7501004 [NCT00159744], A7501005 [NCT00159796]), 977 patients were randomized to flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter), placebo, or oral olanzapine 5-20 mg once daily for 3 weeks. Three populations were defined using baseline depressive symptoms: (1) Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥20 (n = 132); (2) Clinical Global Impression for Bipolar Disorder-Depression (CGI-BP-D) scale severity score ≥4 (n = 170); (3) diagnosis of mixed episodes (n = 302) by investigative site screening. For each population, asenapine and olanzapine were independently compared with placebo using least squares mean change from baseline on depressive symptom measures.
Background
Bipolar disorder is a serious chronic medical condition that typically is cyclical, characterized by manic/hypomanic, depressed, or mixed states, and associated with a high risk for suicide [1, 2] . Although manic episodes are considered the hallmark state of bipolar I disorder, patients spend up to 4 times more symptomatic time in depressed states [3] , and it is depression that primarily contributes to functional disability and high rates of suicide [4] [5] [6] . In 2001, the World Health Organization reported that bipolar affective disorders rank within the top 10 causes of disability among all medical conditions, as measured in years lived with disability [7] .
Although a number of treatment options have been established for acute manic or mixed episodes, including most currently used atypical antipsychotics, few have robust empirical data supportive of efficacy for acute bipolar depression. To date, 2 atypical antipsychotics have received regulatory approval for treatment of bipolar depression. Quetiapine is approved as monotherapy in the United States and European Union for treatment of depressive episodes associated with bipolar disorder [8] and an olanzapine-fluoxetine combination is approved in the United States for the same indication [9] . The adverse events, such as sedation and weight gain, associated with these drugs and the fact that not every patient responds equally well to treatment underscore the need to investigate additional treatment options.
Asenapine is an antipsychotic with a unique pharmacologic profile [10] indicated in the United States in adults for treatment of schizophrenia and as monotherapy or adjunctive therapy with lithium or valproate in the treatment of manic or mixed episodes associated with bipolar I disorder [11] . Asenapine is indicated in the European Union for the treatment of moderate to severe manic episodes associated with bipolar I disorder [12] . The multireceptor pharmacologic profile of asenapine includes antagonism at serotonergic 5-HT 2A and adrenergic α 2 receptors [10] , suggesting that it may effectively treat depressive symptoms. The potential efficacy of asenapine against depressive symptoms is supported by preclinical findings in animal models [13] .
In a pair of randomized placebo-and olanzapine-controlled 3-week trials enrolling patients with bipolar I disorder experiencing a current manic or mixed episode, asenapine demonstrated efficacy superior to placebo as early as day 2 in the treatment of acute mania; the active comparator in those studies (olanzapine) also demonstrated superiority over placebo [14, 15] . In a 9-week extension of these trials, asenapine met criteria for noninferiority to olanzapine in the treatment of mania [16] . In a subsequent 40-week extension designed to assess long-term safety and tolerability, asenapine was well tolerated and maintained efficacy at a level comparable to olanzapine [17] .
The current report describes an exploratory post hoc analysis of the 2 aforementioned 3-week monotherapy trials [14, 15] undertaken to explore the effects of asenapine versus placebo on depressive symptoms in bipolar I patients experiencing acute manic or mixed episodes. Differences in the effects of asenapine versus olanzapine, the active control from these studies, were also assessed.
Methods

Study design
Data from 2 multinational, 3-week, randomized, flexibledose, placebo-and olanzapine-controlled trials (NCT00159744; NCT00159796) were included. Each study was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. The study design and patient populations have been previously described [14, 15] . In brief, the trials were conducted in 10 countries (United States, India, Russia, Ukraine, South Korea, Bulgaria, the Philippines, Romania, Turkey, and Malaysia). Each study included adult patients with a current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of manic or mixed episodes of bipolar I disorder. Included patients were required to have a Young Mania Rating Scale total score ≥20 at screening and baseline, a current manic or mixed bipolar I episode that began ≤3 months before screening, and a documented history of >1 moderate to severe manic or mixed episode, with or without psychotic features. Although limited doses of specific benzodiazepines and sleep medications were allowed during treatment week 1, all other psychotropic medications, including antidepressants, mood stabilizers, and St. John's wort, were prohibited [14, 15] .
Treatment
After single-blind placebo run-in periods of ≤7 days, patients were randomly assigned to 3 weeks of sublingual asenapine (10 mg twice daily [BID] on day 1, flexible-dose 5 or 10 mg BID thereafter), placebo, or oral olanzapine (15 mg once daily [QD] on day 1, flexibledose 5-20 mg QD thereafter) in a 2:1:2 ratio.
Post hoc assessment of depressive symptoms
For these analyses, patients were divided into 3 depression-related populations, each of which is considered to denote clinically-relevant symptoms of depression:
• Baseline Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥20 • Baseline Clinical Global Impression for Bipolar Disorder-Depression severity scale (CGI-BP-D) severity score ≥4 • Baseline diagnosis of a mixed episode Change from baseline on the above scales was evaluated, as was the incidence of depression remission (ie, percentage of patients with MADRS total score ≤12) for each category on days 7 and 21.
In the primary trials, depression severity was assessed using the MADRS, the Positive and Negative Syndrome Scale (PANSS) Marder anxiety/depression factor, and the CGI-BP-D scale. MADRS and PANSS Marder anxiety/depression factor assessments were made on days 1, 7, and 21; the CGI-BP-D was administered at days 1, 2, 4, 7, 14, and 21. Baseline values were the last non-missing assessments on or prior to day 1 (randomization).
Statistical analysis
Post hoc analyses were conducted for observed cases data on selected visits, as well as study Endpoint/Day 21 (using last observation carried forward [LOCF] if missing data occurred), for each data set.
Data from patients in each of the 2 studies were pooled for analysis; demographics and baseline MADRS and CGI-BP-D scores were balanced between treatment groups. Statistical analyses were conducted using an analysis of covariance on observed cases, with baseline values used as covariates; neither study nor the interaction of study × treatment effect were included as factors because no significant differences were found between studies. For continuous measures (MADRS, CGI-BP-D, and PANSS Marder anxiety/depression factor), comparisons were made for asenapine versus placebo, olanzapine versus placebo, and asenapine versus olanzapine on treatment days 7 and 21 using the difference in least squares (LS) mean change from baseline. Within-subject mean changes from baseline on days 7 and 21 were assessed using t-tests. Remission rate comparisons were made using Pearson chi-square tests. All statistical tests were 2-tailed, with statistical significance set at P < 0.05 (trends are reported if the P-values ranged from 0.05-0.09). No adjustments were made for multiple comparisons.
Data are presented in Tables 1 and 2 as the arithmetic mean ± SD and in all figures as the adjusted LS mean ± SE; P-values are based on the LS mean differences for between-group comparisons and arithmetic mean differences for within-subject changes.
Results
Study populations
The total number of randomized patients from the primary studies [14, 15] Baseline demographic characteristics were generally comparable across depression-related categories and treatment groups (Table 1 ). In patients with mixed episodes, the percentage of men in the placebo group was slightly lower than in the asenapine or olanzapine groups. The MADRS and CGI-BP-D severity scores were comparable across groups within each depressionrelated category. Patients experiencing mixed episodes had the lowest MADRS total and CGI-BP-D severity scores at baseline compared with those in other depression-related categories ( Table 1) .
The most common reasons for discontinuation across all depression-related categories were adverse events and withdrawn consent with asenapine, lack of efficacy and withdrawn consent with placebo, and lack of efficacy with olanzapine (Table 1) .
Efficacy
Montgomery-Asberg Depression Rating Scale total score
In patients with baseline MADRS total scores ≥20, LS mean ± SE changes from baseline in MADRS total score with asenapine were significantly greater than placebo on days 7 (-11.3 ± 1.5 vs -4.5 ± 1.6; P = 0.002) and 21 (-13.6 ± 1.6 vs-7.0 ± 1.8; P = 0.009) and were greater than olanzapine on day 7 (-11.3 ± 1.5 vs -6.9 ± 1.2; P = 0.020). Change from baseline MADRS total score with olanzapine was not statistically different from placebo on day 7 (-6.9 ± 1.2 vs -4.5 ± 1.6; P = 0.231) or 21 (-10.6 ± 1.3 vs-7.0 ± 1.8; P = 0.121) ( Figure 1A ).
In patients with baseline CGI-BP-D severity scores ≥4, LS mean ± SE changes in MADRS total score with asenapine were significantly greater than placebo on days 7 (-7.7 ± 1.1 vs -3.6 ± 1.4; P = 0.023) and 21 (-9.9 ± 1.3 vs -5.4 ± 1.6; P = 0.030), with the difference from olanzapine showing a trend towards statistical significance on day 7 (-7.7 ± 1.1 vs -5.3 ± 0.9; P = 0.088). Change from baseline in MADRS total score with olanzapine was not statistically different from placebo at day 7 (-5.3 ± 0.9 vs -3.6 ± 1.4; P = 0.314), but it showed a trend towards statistical significance on day 21 (-8.8 ± 1.0 vs -5.4 ± 1.6; P = 0.084) ( Figure 1B ).
In patients with a mixed episode at baseline, LS mean ± SE changes in MADRS total score were significantly greater with asenapine than placebo on days 7 (-6.7 ± 0.7 vs -3.6 ± 1.0; P = 0.011) and 21 (-8.5 ± 0.8 vs -5.8 ± 1.1; P = 0.040), with the difference from olanzapine showing a trend towards statistical significance on day 7 (-6.7 ± 0.7 vs -5.0 ± 0.7; P = 0.076). Change from baseline in MADRS total score with olanzapine was not statistically different from placebo on days 7 (-5.0 ± 0.7 vs -3.6 ± 1.0; P = 0.244) or 21 (-7.2 ± 0.7 vs -5.8 ± 1.1; P = 0.269) ( Figure 1C ).
Mean ± SD changes from baseline in MADRS total score are summarized in Table 2 . In all treatment groups and across all depression-related categories, within-subject changes from baseline on days 7 and 21 were statistically significant. Montgomery-Asberg Depression Rating Scale-based remission rates
In patients with baseline MADRS total scores ≥20, MADRS remission rates (defined as MADRS total score ≤12) with asenapine were significantly greater than placebo on days 7 (57% vs 17%; P = 0.004) and 21 (70% vs 33%; P = 0.012); remission rate with asenapine on day 7 was significantly greater than olanzapine (57% vs 25%; P = 0.006) and showed a trend towards statistical significance on day 21 (70% vs 48%; P = 0.066). Remission rates with olanzapine on days 7 (25%) and 21 (48%) were not statistically different from placebo (P = 0.478 and P = 0.288, respectively; Figure 2A ). In patients with baseline CGI-BP-D severity score ≥4, MADRS remission rates with asenapine were significantly greater than placebo on day 7 (68% vs 35%; P = 0.014) and showed a trend towards statistical significance on day 21 (68% vs 41%; P = 0.05); the remission rate with asenapine on day 7 was significantly greater than olanzapine (68% vs 45%; P = 0.031). MADRS remission rates with olanzapine were not significantly different from placebo on day 7 (45% vs 35%; P = 0.423) but was significantly greater on day 21 (69% vs 41%; P = 0.027) ( Figure 2B ). In patients with a mixed episode at baseline, MADRS remission rates with asenapine were significantly greater than placebo on days 7 (76% vs 44%; P < 0.001) and 21 (78% vs 56%; P = 0.019); the remission rate with asenapine on day 7 was significantly greater than olanzapine (76% vs 55%; P = 0.007). Remission rates with olanzapine were not significantly different from placebo on day 7 (55% vs 44%; P = 0.259) but was significantly higher with olanzapine on day 21 (74% vs 56%; P = 0.04) ( Figure 2C ).
Clinical Global Impression for Bipolar Disorder-Depression Severity Scale score
In patients with baseline MADRS total scores ≥20, LS mean ± SE changes from baseline in CGI-BP-D severity scores with asenapine were significantly greater than placebo on days 7 (-1.0 ± 0.2 vs -0.4 ± 0.2; P = 0.011) and 21 (-1.4 ± 02 vs -0.7 ± 0.2; P = 0.020) but did not differ statistically from olanzapine on either day 7 (P = 0.320) or 21 (P = 0.622). Changes with olanzapine versus placebo showed a trend towards statistical significance on day 7 (-0.8 ± 0.1 vs -0.4 ± 0.2; P = 0.062) and were significantly greater versus placebo on day 21 (-1.3 ± 0.2 vs -0.7 ± 0.2; P = 0.038) ( Figure 3A ).
In patients with baseline CGI-BP-D severity scores ≥4, LS mean ± SE changes in CGI-BP-D severity scores with asenapine were significantly greater than placebo on day 7 (-1.2 ± 0.2 vs -0.6 ± 0.2; P = 0.015) but not day 21 (-1.6 ± 0.2 vs -1.2 ± 0.23; P = 0.194) and did not differ statistically from olanzapine on either day 7 (P = 0.463) or 21 (P = 0.572). Changes with olanzapine were significantly greater than placebo on day 7 (-1.0 ± 0.1 vs -0.6 ± 0.2; P = 0.047) and showed a trend towards statistical significance on day 21 (-1.7 ± 0.2 vs -1.2 ± 0.2; P = 0.057) ( Figure 3B ).
In patients with a mixed episode at baseline, LS mean ± SE changes in CGI-BP-D severity score with asenapine were significantly greater than placebo on day 7 (-0.7 ± 0.1 vs -0.3 ± 0.1; P = 0.008) and approached significance on day 21 (-1.0 ± 0.1 vs -0.7 ± 0.2; P = 0.089); asenapine and olanzapine did not differ on either day 7 (P = 0.968) or 21 (P = 0.543). Changes with olanzapine were significantly greater than placebo on day 7 (-0.7 ± 0.1 vs -0.3 ± 0.1; P = 0.006) but not on day 21 (-0.9 ± 0.1 vs -0.7 ± 0.2; P = 0.203) ( Figure 3C ).
Mean ± SD changes from baseline CGI-BP-D severity scores are summarized in Table 2 . Within-subject changes from baseline on days 7 and 21 were statistically significant in all treatment groups and across all depression-related categories, with 1 exception. Change in CGI-BP-D score on day 7 in patients with MADRS ≥20 treated with placebo was not statistically significant.
Positive and Negative Syndrome Scale Marder Anxiety/ Depression Factor score
In patients with baseline MADRS total scores ≥20, LS mean ± SE changes from baseline in PANSS Marder anxiety/depression factor scores with asenapine were significantly greater than placebo on days 7 (-3.7 ± 0.6 vs -1.0 ± 0.6; P = 0.001) and 21 (-4.8 ± 0.7 vs -2.3 ± 0.7; P = 0.011) and greater than olanzapine on day 7 (-3.7 ± 0.6 vs -1.7 ± 0.4; P = 0.006). Changes with olanzapine (-1.7 ± 0.4 on day 7 and -3.5 ± 0.5 on day 21) did not statistically differ from placebo (P = 0.310 and 0.179; Figure 4A ).
In patients with baseline CGI-BP-D severity scores ≥4, LS mean ± SE changes in PANSS Marder anxiety/ depression factor scores with asenapine were significantly greater than placebo on day 7 (-2.7 ± 0.4 vs -0.7 ± 0.6; P = 0.005) but not day 21 (-3.1 ± 0.6 vs -1.8 ± 0.7; P = 0.139) and showed a trend towards statistical significance versus olanzapine on day 7 (-2.7 ± 0.4 vs -1.7 ± 0.4; P = 0.066) but not on day 21 (-3.1 ± 0.6 vs -3.5 ± 0.4; P = 0.647). Changes with olanzapine were not significantly different from placebo on day 7 (-1.7 ± 0.4 vs -0.7 ± 0.6; P = 0.133) but were significantly greater on day 21 (-3.5 0.4 vs -1.8 ± 0.7; P = 0.048) ( Figure 4B ).
In patients with a mixed episode, LS mean ± SE changes in PANSS Marder anxiety/depression scores with asenapine were significantly greater than placebo on day 7 (-2.2 ± 0.3 vs -1.0 ± 0.4; P = 0.031) but not day 21 (-3.4 ± 0.4 vs -2.5 ± 0.5; P = 0.129); changes with asenapine and olanzapine did not differ on either day 7 (P = 0.471) or 21 (P = 0.473). Changes with olanzapine (-1.9 ± 0.3 at day 7 and -3.1 ± 0.3 at day 21) were not statistically different from placebo (P = 0.105 and 0.331, respectively; Figure 4C ).
Mean ± SD changes from baseline PANSS Marder anxiety/depression factor score are summarized in Table  2 . With only 1 exception (change in PANSS Marder anxiety/depression factor score on day 7 in patients with MADRS ≥20 treated with placebo were not statistically significant), within-subject changes from baseline on days 7 and 21 were statistically significant in all treatment groups and across all depression-related categories.
Discussion
In this exploratory post hoc analysis, asenapine was statistically superior to placebo in decreasing depressive symptoms in bipolar I disorder patients who were experiencing acute manic or mixed episodes and had clinically relevant depressive symptoms at baseline. Improvement was seen in all depression endpoints (change from baseline on MADRS total score, CGI-BP-D severity score, and PANSS Marder anxiety/depression factor score), as well as on MADRS remission rate. These results are based on analyses using observed cases at selected visits. To address the issue of missing data associated with early study discontinuation, study endpoint (using LOCF) were also reviewed. The LOCF results were in line with those reported from the observed case analysis. The efficacy of asenapine in treating depressive symptoms is supported by in vitro and in vivo preclinical findings. Asenapine has a complex receptor signature, which includes combined antagonism at serotonergic (5-HT 2A and 5-HT 2C ) and adrenergic (α 2 ) receptors; [10] antagonism of these receptor subtypes has been linked to the amelioration of depressive symptoms [18, 19] . Further, asenapine stimulates release of cortical dopamine, noradrenaline, and serotonin [20] and exerts an antidepressant-like effect in animal models [13] .
Although various atypical antipsychotics have been evaluated for treatment of depressive episodes associated with bipolar disorder, the efficacy of these agents has varied substantially (see Table 3 for a summary of published results); currently only olanzapine in combination with fluoxetine and quetiapine monotherapy are approved by the US Food and Drug Administration for the treatment of bipolar depression [8, 9] . In patients with bipolar depression, olanzapine alone and olanzapine in combination with fluoxetine significantly decreased MADRS total scores; placebo-corrected reductions over 3 to 8 weeks of treatment ranged from 3.1-4.4 points with olanzapine alone (versus 1.4-3.6 points for olanzapine alone in the studies included in this analysis) and 5.9-7.8 points when combined with fluoxetine [21] . In the current analysis, olanzapine also tended to improve depressive symptoms, but the olanzapine data appeared to be less consistent than those of asenapine. Additionally, asenapine was statistically superior to olanzapine in several instances (eg, day 7 change in MADRS and PANSS Marder anxiety/depression scores and MADRS remission rate). In the BipOLar DEpRession (ie, BOLDER) trials, quetiapine monotherapy significantly reduced MADRS total score compared with placebo, with placebo-corrected reductions in MADRS total scores of 4-5 points at week 3 and 4-6 points at week 8 reported in patients with bipolar I or II depression [22, 23] .
Despite being approved for adjunctive use in the treatment of major depressive disorder [24] , aripiprazole was no more effective than placebo in alleviating depressive symptoms at endpoint in patients with bipolar I disorder [25] . Risperidone as an adjunct to mood stabilizer treatment was associated with a recovery rate of only 5% in an open-label trial of treatment-resistant patients with bipolar I or II disorder experiencing depressive episodes [26] . Ziprasidone was effective in the treatment of bipolar II disorder patients experiencing major depressive episodes in an open-label trial [27] and in treating depressive symptoms in a post hoc analysis of bipolar patients experiencing dysphoric mania [28] ; however, reviews indicate that ziprasidone was not superior to placebo in controlled studies of patients with bipolar depression [6, 29] .
Although direct comparisons between this exploratory post hoc analysis and randomized clinical trials should be made cautiously, the placebo-corrected changes in MADRS total score in the current analysis (asenapine, 2.6-6.6 points; olanzapine, 1.4-3.6 points) are in the same range as those previously reported in patients with bipolar I or II depression receiving quetiapine or in patients with bipolar I depression receiving olanzapine/ fluoxetine [21] [22] [23] . They are also within the range of values reported in a meta-analysis of controlled bipolar depression trials of quetiapine, olanzapine, and aripiprazole, which reported overall mean MADRS total score reductions of 3.91 points (95% CI, -5.55 to -2.26) versus placebo; this value increased to 4.90 points (95% CI, -6.21 to -3.59) when negative aripiprazole trials were excluded [30] .
In this post hoc analysis, differential effects were observed among depression-related categories, with reductions in depressive symptoms being more robust in patients with baseline MADRS total scores ≥20 than in those with baseline CGI-BP-D severity scores of ≥4 or those experiencing a mixed episode. This variation might result from the rating scales used. Although a MADRS total score of 20 and CGI-BP-D severity score of 4 corresponds to moderate depressive symptoms [31, 32] , respectively, the CGI-BP-D may be less sensitive to change than the MADRS, reducing the ability to detect depressive symptom changes in patients with baseline CGI-BP-D severity score ≥4 (on a 7-point scale) versus in those with a baseline MADRS total scores ≥20 (on a 60-point scale). Comparisons with patients experiencing a mixed episode for the purposes of this post hoc analysis could also be problematic. Due to the higher overall level of variability in baseline depressive symptoms in patients with mixed episodes, the possibility of detecting statistically significant changes in this post hoc analysis may have been compromised.
Conclusions
Depression is considered the predominant burden of bipolar disorder, with depressive states accounting for about 75% of the typical unwell time in bipolar I and II disorder [6] . Therefore, additional effective treatment options are needed for bipolar patients with LS mean ± SE at day 21 Baseline MADRS total score ≥20 Asenapine: -13.6 ± 1.6 (P = 0.009 vs placebo) Olanzapine: -10.6 ± 1.3
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